Device for in vivo delivery of bioactive agents and method of manufacture thereof

• US 8,252,044 B1
• Filed: 11/17/2000
• Issued: 08/28/2012
• Est. Priority Date: 11/17/2000
• Status: Expired due to Term

• Current Assignee: Vactronix Scientific, LLC
• Original Assignee: Advanced Bio Prosthetic Surfaces, Ltd.
• Inventors: Boyle, Christopher T.
• Primary Examiner(s): Pellegrino, Brian E
• Assistant Examiner(s): MILLER, CHERYL L
• Application Number:
  US09/716,146
• Time in Patent Office: 4,302 Days
• Field of Search: 623/1.39, 623/1.4, 623/1.42, 623/1.43, 623/1.45, 623/1.15, 623/1.44
• US Class Current: 623/1.42
• CPC Class Codes: A61F 2/91 made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/91541 Adjacent bands are arranged out of phase
• CPC Class Codes: A61F 2230/001 Figure-8-shaped, e.g. hourglass-shaped
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008

Abstract

The disclosure of the invention provides an implantable structural element for in vivo delivery of bioactive agents to a situs in a body. The implantable structural element may be configured as an implantable prosthesis, such as an endoluminal stent, cardiac valve, osteal implant or the like, which serves a dual function of being prosthetic and a carrier for a bioactive agent. Alternatively, the implantable structural element may simply be an implantable article that serves the single function of acting as a time-release carrier for the bioactive agent.

Claims

1. An endoluminal stent for delivering a bioactive agent to a situs in a body, comprising:

a plurality of vacuum deposited structural elements forming a radially expandable cylindrical member, the plurality of vacuum deposited structural elements including a complex finished geometry, each of the plurality of vacuum deposited structural elements having a wall thickness;

wherein the vacuum deposited structural elements are fabricated of a metal and comprise a base layer and a second layer covering the base layer, further comprising a void space intermediate the base and second layers that is enclosed therebetween;

a plurality of pores passing through the second layer and communicating with the void space such that the void space is open only through the plurality of pores; and

at least one bioactive agent retained within the void space and elutable through the plurality of pores.

2. The endoluminal stent according to claim 1, further comprising a degradable plug residing within the plurality of pores to prohibit release of the at least one bioactive agent until the degradation of the degradable plug.

3. The endoluminal stent according to claim 1, wherein the metal is selected from the group consisting of titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, including zirconium-titanium-tantalum alloys, nitinol, and stainless steel.

4. The endoluminal stent according to claim 1, wherein the bioactive agent further comprises a pharmacologically active agent selected from the group consisting of antibiotic drugs, antiviral drugs, neoplastic agents, steroids, fibronectin, anti-clotting drugs, anti-platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator, urokinase, hirudin, streptokinase, antiproliferatives, methotrexate, cisplatin, fluorouracil, adriamycin, antioxidants, ascorbic acid, beta carotene, vitamin E, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppresents, such as rapomycin, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, vascular endothelial growth factor and fibroblast growth factor, prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide, and integrins.

5. The endoluminal stent according to claim 1, wherein the void space comprises a plurality of independent internal cavities along the length of the structural elements.

6. The endoluminal stent according to claim 1, wherein the metal of the first and second layers has at least one surface thereof having controlled heterogeneities thereupon.

7. The endoluminal stent according to claim 6, wherein the controlled heterogeneities are selected from the group consisting of grain size, grain phase, grain material composition and surface topography.

8. The endoluminal stent according to claim 6, wherein the controlled heterogeneities define polar and non-polar binding sites for binding blood plasma proteins.

9. The endoluminal stent according to claim 6, wherein the controlled heterogeneities are dimensioned to have a blood contact surface area substantially similar in size to endothelial cell surface integrin clusters.

10. The endoluminal stent according to claim 6, wherein the controlled heterogeneities define cell-adhesion domains having interdomain boundaries less than the surface area of a human endothelial cell.

11. The endoluminal stent according to claim 6, wherein the controlled heterogeneities form binding domains having a repeating pattern with no more than about 2 μ

m border to border spacing between adjacent binding domains.

12. The endoluminal stent according to claim 6, wherein the controlled heterogeneities are dimensioned to have a blood contact surface area of about less than 6 μ

m².

13. The endoluminal stent according to claim 6, wherein the controlled heterogeneities have a blood contact surface less than or equal to about 10 μ

m and an inter-heterogeneity boundary between about 0 and 2 μ

m.